News: Insmed Inc (INSM.OQ)
10.04USD
4:00pm EDT
$0.32 (+3.29%)
$9.72
$9.91
$10.15
$9.70
309,568
115,828
$14.30
$2.86
Mon, Jul 1 2013
UPDATE 2-Insmed's lung infection drug fares no better than rival, shares fall
* Drug shows smaller improvement in lung capacity vs rival
Insmed's lung infection drug succeeds in late-stage trial
July 1 - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.
- Insmed Incorporated - Special Call
- Insmed Lung Antibiotic Passes Test But Falls Short of Investor Expectations
- Wednesday's Small Cap Biotech Catalyst Watch And Trade List
- BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market
- 2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
- Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Press Releases
- Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
- Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment
- Insmed To Present At Two Upcoming Investor Conferences
- Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012
- Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
- Insmed to Host 2012 Third Quarter Earnings Conference Call
- NuPathe Announces Closing of $28 Million Private Placement and Changes to Its Board of Directors
- Insmed Announces Pricing of Approximately $26 Million Direct Public Offering
- Insmed Appoints Will Lewis as President and Chief Executive Officer
- Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
